Piloting 'mPal,' a Multilevel Strategy for Palliative Care Implementation
The purpose of this study is to assess the feasibility and acceptability of mPal, a multilevel implementation strategy to improve palliative care use among advanced stage lung cancer patients receiving cancer treatment.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 13, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Laurie McLouth
- Interventions being studied
- Behavioral: mPal
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- new or recurrent AJCC stage IIIb-IV non-small cell lung cancer or extensive stage small cell lung cancer
- ECOG performance status 0-3/Karnofsky 40-100
- at least three weeks into active oncologic treatment (chemotherapy, immunotherapy, chemo-immunotherapy)
- unstable brain metastases
- Cognitive (i.e., dementia) or psychiatric condition (e.g., psychotic disorder) for which participating would be inappropriate
- Receiving palliative care
- Unable to speak and read English
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of KentuckyLexington, Kentucky
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 13, 2025. Always confirm current availability with the study team.